|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||David Pejoski, CEO|
Adoram Therapeutics is a preclinical stage UNIGE spin-off biotech that is discovering small molecules with a disruptive ‘allosteric’ mode of action, providing both improved efficacy & safety compared to conventional drugs. Our recently patented lead asset is a 3rd generation orally available metabolic immune-checkpoint inhibitor to treat orphan drug-designated solid tumors. Our other active R&D programs target CNS disorders & inflammation.